Treatment of Human Immunodeficiency Virus-Associated Facial Lipoatrophy With Hyaluronic Acid Filler Mixed With Micronized Cross-Linked Acellular Dermal Matrix

Nursing and Health Professions

• Patient 100%
• Lipoatrophy 58%
• Physician 16%
• Filler 16%
• Hyaluronic Acid 16%
• Acellular Dermal Matrix 16%
• Patient with Human Immunodeficiency Virus 16%
• Follow up 8%
• Side Effect 8%
• Adverse Event 8%
• Combination Therapy 8%
• Wilcoxon Signed Ranks Test 8%
• Analysis of Variance 8%
• Evaluation Study 8%
• Procedures 8%
• Time 8%
• Post Hoc Analysis 8%
• Parameters 8%
• Volume 8%
• Camera 8%
• Injection 8%
• Highly Active Antiretroviral Therapy 8%
• Subcutaneous Nodule 8%

Medicine and Dentistry

• Lipoatrophy 58%
• Human Immunodeficiency Virus 33%
• Therapeutic Procedure 33%
• Restylane 16%
• Acellular Dermal Matrix 16%
• Inpatient 16%
• Efficacy Study 16%
• Combination Therapy 8%
• Side Effect 8%
• Adverse Event 8%
• Follow up 8%
• Analysis of Variance 8%
• Wilcoxon Signed Ranks Test 8%
• Post-Hoc Analysis 8%
• Satisfaction 8%
• Evaluation Study 8%
• Subcutaneous Nodule 8%
• Highly Active Antiretroviral Therapy 8%
• Injection 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Lipoatrophy 58%
• HIV 33%
• Filler 16%
• Hyaluronic Acid 16%
• Adverse Event 8%
• Side Effect 8%
• Subcutaneous Nodule 8%